180 Life Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

180 Life Sciences yıllık ortalama 0.7% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.3% annual.

Anahtar bilgiler

0.7%

Kazanç büyüme oranı

35.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-83.6%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

180 Life Sciences to raise $6.5M in direct stock offering

Jul 18

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

Sep 08

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

Feb 17

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

Nov 27

Gelir ve Gider Dağılımı

180 Life Sciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:ATNF Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	-3	5	2
30 Jun 24	-13	7	2
31 Mar 24	-16	8	3
31 Dec 23	-20	11	3
30 Sep 23	-40	14	3
30 Jun 23	-52	15	3
31 Mar 23	-45	16	3
31 Dec 22	-39	15	2
30 Sep 22	-16	13	4
30 Jun 22	24	13	4
31 Mar 22	-3	12	4
31 Dec 21	-20	12	4
30 Sep 21	-30	11	3
30 Jun 21	-50	7	3
31 Mar 21	-26	5	2
31 Dec 20	-12	3	2
30 Sep 20	-29	20	3
30 Jun 20	-28	20	3
31 Mar 20	-28	20	3
31 Dec 19	-25	19	2
30 Sep 19	-4	3	1
30 Jun 19	-6	4	1

Kaliteli Kazançlar: ATNF şu anda kârlı değil.

Büyüyen Kar Marjı: ATNF şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ATNF kârlı değildir, ancak son 5 yılda zararlarını yılda 0.7% oranında azaltmıştır.

Büyüme Hızlandırma: ATNF 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ATNF kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ATNF hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -83.61% ) sahiptir.

180 Life Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024

180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees

180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule

180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024

180 Life Sciences Corp. Announces Chief Financial Officer Changes

180 Life Sciences Corp. Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. Provides Non-Compliance Update

180 Life Sciences Corp. Provides Non-Compliance Update

New major risk - Financial position

180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A)

180 Life Sciences Receives a Letter from Nasdaq

High number of new directors

180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency

180 Life Sciences Receives Non-Compliance Notice From Nasdaq

180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq

New minor risk - Share price stability

180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake

180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment

180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

No longer forecast to breakeven

Price target decreased to US$4.00

High number of new and inexperienced directors

180 Life Sciences Receives Non-Compliance Letter from Nasdaq

180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million.

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Price target decreased to US$5.00

High number of new and inexperienced directors

180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022

180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion

180 Life Sciences Corp. Forms Scientific Advisory Board

Lead Independent Director recently bought US$103k worth of stock

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences Corp. announced that it has received $15 million in funding

180 Life Sciences Corp. announced that it expects to receive $15 million in funding

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. announced delayed annual 10-K filing

180 Life Sciences Receives Extension Until June 30, 2021 to Regain Compliance from Nasdaq

180 Life Sciences Corp. announced that it expects to receive $11.6662 million in funding

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

New 90-day high: US$6.72

180 Life Sciences Corp. Announces Management Changes

180 Life Sciences Corp. Appoints Ozan Pamir to Serve as the Interim Chief Financial Officer